CTLA4 and neoplasm: Monoclonal antibodies that block immune checkpoint receptors, such as cytotoxic T-lymphocyte antigen (CTLA)-4, programmed death (PD)-1, and its ligand PD-L1, have shown broad-spectrum activity against a wide range of tumor types, leading to prolonged survival in many patients.